OncoTherapy Science, Inc. (TYO:4564)
Japan · Delayed Price · Currency is JPY 22.00
-1.00 (-4.35%)
Sep 16, 2026, 3:30 PM JST
OncoTherapy Science Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 777 | 808 | 750 | 610 | 1,134 | 1,153 |
Revenue Growth | -8.70% | 7.73% | 22.95% | -46.21% | -1.65% | 247.29% |
Gross Profit Gross Profit Growth | -499 | -521 | -503 | -855 | -676 | -1,617 |
Operating Income Operating Income Growth | -791 | -810 | -797 | -1,120 | -1,107 | -2,053 |
Net Income Net Income Growth | -884 | -910 | -815 | -1,288 | -1,118 | -2,571 |
Earnings Per Share EPS Growth | -2.47 | -2.77 | -3.12 | -6.05 | -5.80 | -13.71 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Pharmaceutical Research and Development and Related Businesses Pharmaceutical Research and Development and Related Businesses Growth | 2.23 | 2.64 | 3.29 | 0.7 | 9.37 | 7.33 |
Cancer Precision Medicine Related Business Cancer Precision Medicine Related Business Growth | 775.83 | 806.2 | 747.06 | 609.69 | 1,126 | 1,155 |
Unallocated Adjustment Unallocated Adjustment Growth | -0.25 | -0.31 | -0.29 | -0.27 | -0.24 | -8.5 |
Total Total Growth | 777.81 | 808.53 | 750.05 | 610.12 | 1,135 | 1,154 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Cash (Debt) Net Cash Growth | 2,326 | 2,089 | 833 | 527 | 1,117 | 1,836 |
Net Cash Growth | 89.41% | 150.78% | 58.06% | -52.82% | -39.16% | -36.67% |
Net Cash Per Share Net Cash Per Share Growth | 6.49 | 6.36 | 3.19 | 2.48 | 5.80 | 9.79 |
Cash & Investments Cash & Investments Growth | 2,326 | 2,089 | 833 | 527 | 1,117 | 1,836 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | -922 | -815 | -1,227 | -794 | -2,073 |
Capital Expenditures CapEx Growth | - | -62 | - | -2 | -4 | -456 |
Free Cash Flow Free Cash Flow Growth | - | -984 | -815 | -1,229 | -798 | -2,529 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | -64.22% | -64.48% | -67.07% | -140.16% | -59.61% | -140.24% |
Operating Margin | -101.80% | -100.25% | -106.27% | -183.61% | -97.62% | -178.06% |
Pretax Margin | -113.51% | -112.38% | -108.40% | -210.82% | -98.41% | -222.90% |
Profit Margin | -113.77% | -112.62% | -108.67% | -211.15% | -98.59% | -222.98% |
FCF Margin | - | -121.78% | -108.67% | -201.47% | -70.37% | -219.34% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 16, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Forward PE | - | 25.49 | 25.49 | 25.49 | 25.49 | 25.49 |
PS Ratio | 12.08 | 9.97 | 10.14 | 7.14 | 7.98 | 11.53 |